Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07048314 · ClinicalTrials.gov registry record · Phase 1
Stem Cells for Erectile Dysfunction Post RALP
A Phase 1 study, sponsored by The Methodist Hospital Research Institute.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT07048314: Recruiting Phase 1 study, sponsored by The Methodist Hospital Research Institute.
NCT07048314 is a Phase 1 study that is actively recruiting participants, run by The Methodist Hospital Research Institute. The registered enrollment target is 40 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07048314, a Phase 1 study, is actively recruiting participants, sponsored by The Methodist Hospital Research Institute.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
This is a phase 1/2 single center, pilot study to assess safety and efficacy of allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) and to evaluate the timing and combination effects of active treatment versus placebo in promoting the recovery of erectile function in patients undergoing radical retropubic prostatectomy (RALP) of localized prostate cancer.
Primary Outcome
IIEF-5 is a tool to asses erectile dysfunction base on five questions about confidence, hardness, maintenance and satisfaction of erections. Score: 1 to 25.
Interventions
- DRUG Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) at the doctor's office
- DRUG Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) in the OR
- DRUG Placebo in the OR
- DRUG Placebo in clinic
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2026-07-07 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 1 |
What NCT07048314 shows while recruiting
NCT07048314 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower).
The record links to 0 conditions, and to 4 interventions - of which Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) at the doctor's office is the first listed.
NCT07048314 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07048314 about?
NCT07048314 is a clinical study titled "Stem Cells for Erectile Dysfunction Post RALP". This is a phase 1/2 single center, pilot study to assess safety and efficacy of allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) and to evaluate the timing and combination effects of active treatment versus placebo in promoting the recovery of erectile function in patients undergoing ra...
What is the current status of trial NCT07048314?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2026-07-07. Estimated completion is 2027-06-30.
What interventions are being tested in trial NCT07048314?
The interventions under investigation include: Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) at the doctor's office (DRUG), Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) in the OR (DRUG), Placebo in the OR (DRUG), Placebo in clinic (DRUG).
Who is sponsoring clinical trial NCT07048314?
This trial is sponsored by The Methodist Hospital Research Institute, which has 126 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07048314's enrollment target sits among peer trials
40 1130th of 2000 higher than 810 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI